Blood cancers

Venetoclax approved for AML patients ineligible for intensive chemo

The TGA has approved the provisional registration of venetoclax as part of combination therapy for patients with newly diagnosed AML who are ineligible for intensive chemotherapy. The extension of indication for the BCL-2 inhibitor (Venclexta – 10 mg, 50 mg and 100 mg film coated tablets) from its initial use in CLL is supported by ...

Already a member?

Login to keep reading.

© 2021 the limbic